A WHO technical consultation concluded that the available evidence indicates an association between use of progestogen injectables and an increased risk of acquiring HIV. WHO issued revised guidance on the use of progestogen-only injectables (norethisterone enanthate [NET-EN] and depot medroxyprogesterone acetate [DMPA], in both intramuscular and subcutaneous forms by women at high risk of HIV acquisition. Under the revised guidance, progestogen-only injectables are now reclassified from category 1* (no restriction) to category 2 (benefits outweigh risks) for women at high risk of HIV.